Departments and research groups

Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA (2024)
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
Oncoimmunology, 14 (1), 2440967
DOI 10.1080/2162402X.2024.2440967, PubMed 39703053

Pinto R, Vedeld HM, Lind GE, Jeanmougin M (2024)
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework
Mol Oncol (in press)
DOI 10.1002/1878-0261.13772, PubMed 39696831

Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Front Immunol, 15, 1480183
DOI 10.3389/fimmu.2024.1480183, PubMed 39687621

Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2024)
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Cancer Res (in press)
DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396

Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA (2024)
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
Oncoimmunology, 14 (1), 2440967
DOI 10.1080/2162402X.2024.2440967, PubMed 39703053

Pinto R, Vedeld HM, Lind GE, Jeanmougin M (2024)
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework
Mol Oncol (in press)
DOI 10.1002/1878-0261.13772, PubMed 39696831